All Stories

  1. The impact of radiotherapy on the hypothalamo-pituitary axis: old vs new radiotherapy techniques
  2. A study of acromegaly-associated headache with somatostatin analgesia
  3. Paltusotine, a novel oral somatostatin receptor ligand in the management of acromegaly
  4. Adjuvant Rituximab – exploratory trial in young people with Graves’ disease
  5. ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises
  6. Outcomes of 756 patients with differentiated thyroid cancer and excellent response to treatment: An evidence‐based paradigm for long‐term surveillance strategies
  7. Interpretation of the endocrinology of hospital inpatients
  8. The severity of obstructive sleep apnoea does not
  9. Management of persistent acromegaly following primary therapy: The current landscape in the UK
  10. Performance of the unilateral AV/IVC index in primary hyperaldosteronism subtype prediction: A validation study in a single tertiary centre
  11. Construction of a predictive scoring system as a guide to screening and confirmation of the diagnosis of primary aldosteronism
  12. Is Chemotherapy Implicated in the Development of Hypopituitarism in Childhood Cancer Survivors?
  13. Can We Discharge Dynamically Risk-Stratified Low-Risk (Excellent Response to Treatment) Thyroid Cancer Patients After 5 Years of Follow-Up?
  14. Hypothalamo‐pituitary axis irradiation dose thresholds for development of hypopituitarism in adult‐onset gliomas
  15. Glucocorticoid management of adrenal insufficiency in the United Kingdom: assessment using real-world data
  16. Management of glucocorticoids following adrenalectomy for ACTH-independent Cushing's syndrome
  17. Mortality data from the European Adrenal Insufficiency Registry-Patient characterization and associations
  18. Late-onset X-linked adrenal hypoplasia (DAX-1, NR0B1): two new adult-onset cases from a single center
  19. Endemic goitre and hypothyroidism in an adult female patient dependent on total parenteral nutrition
  20. Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Results from a 5-years prospective study
  21. In Response to: Prednisolone Replacement Therapy Mimics the Circadian Rhythm More Closely than Other Glucocorticoids
  22. Diagnostic challenges and management of a patient with acromegaly due to ectopic growth hormone-releasing hormone secretion from a bronchial carcinoid tumour
  23. Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity - data from the EU-AIR
  24. Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency
  25. A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline
  26. Pituitary dysfunction following cranial radiotherapy for adult-onset nonpituitary brain tumours
  27. Response to ‘How we define hyponatremia?’
  28. The modulation of corticosteroid metabolism by hydrocortisone therapy in patients with hypopituitarism increases tissue glucocorticoid exposure
  29. The diagnosis and management of inpatient hyponatraemia and SIADH
  30. Endocrine sequelae beyond 10 years in survivors of medulloblastoma
  31. The effects of pituitary and thyroid disorders on haemostasis: potential clinical implications
  32. Lanreotide autogel in acromegaly – a decade on
  33. European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy
  34. Atypical Presentation of Riedel’s Thyroiditis: Multifocal Nodular Fibrosis and Resolution with Levothyroxine
  35. Serum vascular endothelial growth factor (VEGF) is elevated in GH deficient adults
  36. Partial Growth Hormone Deficiency is Associated With an Adverse Cardiovascular Risk Profile and Increased Carotid Intima-Medial Thickness.
  37. Current therapy and drug pipeline for the treatment of patients with acromegaly
  38. GH sensitivity of GH-deficient adults is dependent on gender but not timing of onset
  39. Hypogonadotropic hypogonadism: a consequence of Chiari-I malformation
  40. A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly
  41. Resolution of secondary amenorrhoea following withdrawal of dihydocodeine
  42. The Diagnosis of Partial Growth Hormone Deficiency in Adults with a Putative Insult to the Hypothalamo-Pituitary Axis
  43. The Impact of Short-Term Fasting on the Dynamics of 24-Hour Growth Hormone (GH) Secretion in Patients with Severe Radiation-Induced GH Deficiency
  44. A Densitometric and Morphometric Analysis of the Skeleton in Adults with Varying Degrees of Growth Hormone Deficiency
  45. Quality of Life in Adult Growth Hormone Deficiency
  46. The Phenotype of Adults with Partial Growth Hormone Deficiency
  47. Insulin sensitivity is impaired in adults with varying degrees of GH deficiency
  48. Impact of Growth Hormone Status on Body Composition and the Skeleton
  49. Central and peripheral actions of somatostatin on the growth hormone–IGF-I axis
  50. The Novel Somatostatin Ligand (SOM230) Regulates Human and Rat Anterior Pituitary Hormone Secretion
  51. Growth Hormone Replacement Decreases Plasma Levels of Matrix Metalloproteinases (2 and 9) and Vascular Endothelial Growth Factor in Growth Hormone-Deficient Individuals
  52. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status
  53. Adults with Partial Growth Hormone Deficiency Have an Adverse Body Composition
  54. Low Bone Mass Is an Infrequent Feature of the Adult Growth Hormone Deficiency Syndrome in Middle-Age Adults and the Elderly
  55. Acquired prolactin deficiency indicates severe hypopituitarism in patients with disease of the hypothalamic-pituitary axis
  56. Adult growth hormone replacement: current understanding
  57. Plasma total homocysteine concentrations in adults with growth hormone (GH) deficiency: effects of GH replacement
  58. Adult Growth Hormone Replacement: Lessons Learned and Future Direction
  59. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults
  60. Timing of onset of growth hormone deficiency is a major influence on insulin-like growth factor I status in adult life
  61. Lipoprotein lipase gene variants relate to presence and degree of microalbuminuria in Type II diabetes
  62. Low-dose GH replacement improves the adverse lipid profile associated with the adult GH deficiency syndrome
  63. Spinal irradiation impairs the osteo-anabolic effects of low-dose GH replacement in adults with childhood-onset GH deficiency
  64. Differential Effects of GH Replacement on the Components of the Leptin System in GH-Deficient Individuals
  65. GH-Deficient Survivors of Childhood Cancer: GH Replacement during Adult Life
  66. The diagnosis of growth hormone deficiency (GHD) in successfully treated acromegalic patients
  67. Survivors of child-hood cancer: long-term endocrine and metabolic problems dwarf the growth disturbance.
  68. Growth hormone: current and future therapeutic applications
  69. Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiency
  70. Clinical presentation of PCOS following development of an insulinoma: Case Report
  71. Survivors of childhood cancer: long-term edocrine and metabolic problems dwarf the growth distrubance
  72. Influences on quality of life in GH deficient adults and their effect on response to treatment
  73. Gonadotrophin-releasing hormone analogues: a novel treatment for premenstrual asthma
  74. Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults